Phospho-specific antibodies’ typical purpose is to enable researchers to detect changes in proteins. They will exclusively bind to the amino acid sequence on a protein that has been phosphorylated (which is both a physical & chemical change) and do not bind to the same amino acid sequence on said protein if it lacks said phosphorylation. This aids in being able to clearly see and understand the data produced from this particular protein modification.
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Stathmin 1(Phospho-Ser38) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from K562 cells untreated or treated with starvation using Stathmin 1(Phospho-Ser38) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using HDAC5(Phospho-Ser498) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with serum starvation using HDAC5(Phospho-Ser498) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using p53(Phospho-Ser6) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from HT29 and Hela cells untreated or treated with UV using p53(Phospho-Ser6) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Smad3(Phospho-Ser425) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated or treated with EGF using Smad3(Phospho-Ser425) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
WB (Western Blot) (Western blot analysis of extracts from 293 cells, treated with starve or calf intestinal phosphatase (CIP), using SHP-2 (Phospho-Tyr580) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using SHP-2(Phospho-Tyr580) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
WB (Western Blot) (Western blot analysis of extracts from C2C12 cells, treated with Anisomycin or calf intestinal phosphatase (CIP), using MEF2A (Phospho-Thr312) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using MEF2A(Phospho-Thr312) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using MEF2A(Phospho-Thr312) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using PKR(Phospho-Thr446) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human colon carcinoma tissue using PKR(Phospho-Thr446) Antibody (left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from K562 cells using PKR(Phospho-Thr446) Antibody (Lane 2) and the same antibody preincubated with blocking peptide(Lane1).)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using MSK2 (Phospho-Thr568) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from 293 cells, treated with H2O2 (100uM, 15mins), using MSK2 (Phospho-Thr568) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatogramphy usi
WB (Western Blot) (Something like SH-SY5Y cells expressing GFP-LC3-WT or-S12D treated with rapamycin or vehicle for 1h.)
WB (Western Blot) (Immunoblots of SH-SY5Y cells treated with MPP+ for 24h was probed with AAA285518. The data shows that treatment with MPP+ showed no significant change in level of LC3.)
WB (Western Blot) (Immunoblots of SH-SY5Y cells treated with rapamycin for 1 h was probed with AAA285518. The data shows that treatment with rapamycin showed no significant change in level of LC3.)
DB (Dot Blot) (Dot blot analysis of Phospho-LC3 (APG8a) - S12 Antibody and Nonphospho-LC3 (APG8a) Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Immunoblots of phosphorylated LC3 (phospho-LC3) in CHO cell culture. LC3 and LC3 S12A mutant vectors were transfected into CHO cells. The cell lysates were separated with SDS-PAGE and blotted with anti-phospho-LC3 S12 antibody. LC3 = microtubule-associated protein light chain-3; S12A = replacement of the amino acid position 12 serine of LC3 with alanine. WT = wildtype LC3-transfected cell lysates; S12A = LC3 S12A mutant-transfected cell lysates; Empty vector = vector with no LC3 gene. Molecular size: LC3-I = 16kDa, and LC3-II = 14 kDa)
IF (Immunofluorescence) (Confocal immunofluorescent analysis of Phospho-HER4-Y1162 Antibody with MCF-7 cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).DAPI was used to stain the cell nuclear (blue).)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (Phospho-HER4-Y1162 Antibody was used to detect Phospho-HER4-Y1162 in FG pancreatic carcinoma cell line lysate.FG pancreatic carcinoma cells treated with or without EGF (50ng/ml) for 15 minPhospho-HER4-Y1162 Antibody was used at 1:750 in 3% BSA.Data and protocol kindly provided by Dr. Weis of Cheresh Lab, UCSD.)
DB (Dot Blot) (Dot blot analysis of ERBB2 Antibody (Phospho Y1005) Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
IF (Immunofluorescence) (Fluorescent confocal image of MCF7 cells stained with phospho-ERBB2-Y1005 antibody. MCF7 cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated with AAA284919 phospho-ERBB2- Y1005 primary antibody (1:100, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 ug/ml, 5 min). Note the highly specific localization of the phospho-ERBB2-Y1005 to the plasma membrane and cytoplasm.)
WB (Western Blot) (Western blot analysis of extracts from A431 cell,untreated or treated with EGF,using phospho-ERBB2-Y1005 (left) or ErBB2 antibody(right).)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-IL6ST-Y905 Phospho-specific Pab (AAA283923) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
DB (Dot Blot) (Dot blot analysis of anti-hSeparase-S801 Phospho-specific Pab on nitrocellulose membrane. 50ng of nonphospho-peptide or phospho-peptide were adsorbed on their respective dots. Antibody working concentration was 0.5ug per ml.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-ErbB2-pY1248(M) Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
WB (Western Blot) (Western blot analysis of extracts from A431 cells,untreated or treated with EGF,100ng/ml, using phospho-ERBB2-Y1248(left) or ERBB2 antibody(right))
WB (Western Blot) (Western blot analysis of extracts from A431 cells,untreated or treated with EGF,100ng/ml, using phospho-ERBB2-pY1248(L)(left) or ERBB2 antibody(right))
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (The anti-Phospho-CDC6-S54 Pab is used in Western blot to detect Phospho-CDC6-S54 in Ramos tissue lysate)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (The anti-Phospho-p27Kip1-S178 Pab is used in Western blot to detect Phospho-p27Kip1-S178 in HL60 tissue lysate)
DB (Dot Blot) (Dot blot analysis of Phospho-SNAP25-pT138 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
WB (Western Blot) (The anti-Phospho-SMAD3-S213 Pab is used in Western blot to detect Phospho-SMAD3-S213 in Ramos tissue lysate)
IHC (Immunohiostchemistry) (Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by AEC staining. This data demonstrates the use of this antibody for immunohistochemistry; clinical relevance has not been evaluated. BC = breast carcinoma; HC = hepatocarcinoma.)
WB (Western Blot) (All lanes : Anti-SMAD3(S213) Antibody at1:1000 dilution Lane 1: HACAT whole cell lysateLane 2: HT-1080 whole cell lysate Lane 3: Helawhole cell lysate Lysates/proteins at 20 ?g perlane. Secondary Goat Anti-Rabbit IgG, (H+L),Peroxidase conjugated at 1/10000 dilution.Predicted band size : 48, 43 kDa Blocking/Dilution buffer: 5% NFDM/TBST.)
DB (Dot Blot) (Dot blot analysis of anti-Phospho-SMAD2-S118 Antibody on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
IF (Immunofluorescence) (Confocal immunofluorescent analysis of Phospho-SMAD2-S118 Antibody with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red).)
DB (Dot Blot) (Dot blot analysis of Phospho-ERBB2-T1172 Antibody Phospho-specific Pab on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.6ug per ml.)
IF (Immunofluorescence) (Fluorescent confocal image of MCF7 cells stained with phospho-ERBB2-T1172 antibody. MCF7 cells were fixed with 4% PFA (20 min), permeabilized with Triton X-100 (0.2%, 30 min). Cells were then incubated with AAA289958 phospho-ERBB2-T1172 primary antibody (1:100, 2 h at room temperature). For secondary antibody, Alexa Fluor 488 conjugated donkey anti-rabbit antibody (green) was used (1:1000, 1h). Nuclei were counterstained with Hoechst 33342 (blue) (10 ug/ml, 5 min). Note the highly specific localization of the phospho-ERBB2-T1172 to the plasma membrane.)
DB (Dot Blot) (Dot blot analysis of anti-raptor-pS863 Pab (RB13350) on nitrocellulose membrane. 50ng of Phospho-peptide or Non Phospho-peptide per dot were adsorbed. Antibody working concentrations are 0.5ug per ml.)
IHC (Immunohiostchemistry) (Dilution: Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications.)
WB (Western Blot) (Dilution: Western Blot: 1/500 - 1/2000. Immunohistochemistry: 1/100 - 1/300. ELISA: 1/10000. Not yet tested in other applications.)
ICC (Immunocytochemistry) (Detection of human Phospho-Aurora A (T288) by immunocytochemistry. Samples: NBF-fixed asynchronous HeLa cells. Mock phosphatase treated section (left) or calf intestinal phosphatase-treated section (right) immunostained for Phospho-Aurora A. Antibody: Affinity purified rabbit anti-Phospho-Aurora A (T288) (Cat. No. AAA213768) used at a dilution of 1:250. Detection: Anti-rabbit IgG-FITC conjugated (Cat. No. used at a dilution of 1:100.)
ICC (Immunocytochemistry) (Detection of human Phospho-Aurora A (T288) by immunocytochemistry. Samples: NBF-fixed asynchronous HeLa cells. Antibody: Affinity purified rabbit anti-Phospho-Aurora A (T288) (Cat. No. AAA213768) used at a dilution of 1:250. Detection: Anti-rabbit IgG-FITC conjugated (Cat. No. used at a dilution of 1:100.)
IHC (Immunohiostchemistry) (Detection of mouse Phospho-MCM2 (S53) by immunohistochemistry. Samples: FFPE serial sections of mouse teratoma. Mock phosphatase treated section (left) or calf intestinal phosphatase treated section (right) immunostained for Phospho-MCM2 (S53). Antibody: Affinity purified rabbit anti-Phospho-MCM2 (S53) (Cat. No. AAA213769 Lot3) used at a dilution of 1:250. Detection: DAB)
IHC (Immunohistochemistry) (Detection of human Phospho-MCM2 (S53) by immunohistochemistry. Samples: FFPE serial sections of human breast adenocarcinoma. Mock phosphatase treated section (left) or calf intestinal phosphatase treated section (right) immunostained for Phospho-MCM2 (S53). Antibody: Affinity purified rabbit anti-Phospho-MCM2 (S53) (Cat. No. AAA213769 Lot3) used at a dilution of 1:250. Detection: DAB)
WB (Western Blot) (Western blot analysis of lysates from K562 cells treated with insulin 0.01U/ml 15', using AKT1/3 (Phospho-Tyr437/434) Antibody. The lane on the right is blocked with the phospho peptide.)
IHC (Immunohistochemistry) (Immunohistochemistry analysis of paraffin-embedded human brain, using AKT1/3 (Phospho-Tyr437/434) Antibody. The picture on the right is blocked with the phospho peptide.)
Purified from rabbit antiserum by affinity-chromatography using phospho peptide. The antibody against non-phospho peptide was removed by chromatography using corresponding non-phospho peptide.
IHC (Immunohiostchemistry) (Immunohistochemistry of E Cadherin (phospho-Ser838/Ser840) in paraffin-embedded Human breast cancer tissue using E Cadherin (phospho-Ser838/Ser840) Rabbit mAb at dilution 1/50)
WB (Western Blot) (Western blot detection of E Cadherin (phospho-Ser838/Ser840) in HepG2,U2OS,U251,Lncap using E Cadherin (phospho-Ser838/Ser840) Rabbit mAb(1:1000 diluted))
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using c-Jun(Phospho-Thr91) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from 293 cells untreated or treated with UV using c-Jun(Phospho-Thr91) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using c-Jun(Phospho-Thr93) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Hela cells untreated or treated with PMA using c-Jun(Phospho-Thr93) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using EGFR(Phospho-Tyr1092) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from A431 cells untreated or treated with EGF using EGFR(Phospho-Tyr1092) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using PAK1/PAK2/PAK3(Phospho-Thr423/Thr402/Thr421) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using PAK1/PAK2/PAK3(Phospho-Thr423/Thr402/Thr421) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from 3T3 cells, treated with Anisomycin or calf intestinal phosphatase (CIP), using ASK1 (Phospho-Ser83) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using ASK1(Phospho-Ser83) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from K562 cells using ASK1(Phospho-Ser83) Antibody(Lane 2) and the same antibody preincubated with blocking peptide(Lane1).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from JK cells, treated with G-CSF or calf intestinal phosphatase (CIP), using p62Dok (phospho-Tyr362) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using p62Dok(Phospho-Tyr362) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from Jurkat cells untreated or treated with insulin using p62Dok(phospho-Tyr362) Antibody.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using syk(phospho-Tyr323) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using syk(Phospho-Tyr323) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
WB (Western Blot) (Western blot analysis of extracts from JK cells untreated or treated with H2O2 for the indicated times, using syk(phospho-Tyr323) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed A549 cells using PKA alpha/beta CAT (Phospho-Thr197) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human colon carcinoma tissue using PKA alpha/beta CAT (Phospho-Thr197) antibody (left)or the same antibody preincubated with blocking peptide (right).)
WB (Western Blot) (Western blot analysis of extracts from mouse brain cells using PKA alpha/beta CAT (Phospho-Thr197) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from C6 cells using Tau(Phospho-Ser404) Antibody.)
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed Hela cells using Tau(Phospho-Ser404) Antibody.)
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded rat hippocampal region tissue from a model with Alzheimer)
WB (Western Blot) (Western blot analysis of extracts from C6 cells, treated with calf intestinal phosphatase (CIP), using Tau (Phospho-Ser404) Antibody.)
Immunofluorescence, Immunohistochemistry, Western Blot
Purity
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using Trk A (Phospho-Tyr701) antibody. The picture on the right is treated with the synthesized peptide.)
WB (Western Blot) (Western blot analysis of extracts from mouse brain cells, using Trk A (Phospho-Tyr701) antibody. The lane on the right is treated with the synthesized peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
WB (Western Blot) (Western blot analysis of extracts from HT29 cells, treated with Hydroxyurea or calf intestinal phosphatase (CIP), using Aurora A (phospho-Thr288) Antibody.)
IHC (Immunohistochemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue using Aurora A(Phospho-Thr288) Antibody(left) or the same antibody preincubated with blocking peptide(right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IF (Immunofluorescence) (Immunofluorescence staining of methanol-fixed HeLa cells using Chk2 (Phospho-Thr383) Antibody.)
WB (Western Blot) (Western blot analysis of extracts from COS7 cells treated with UV using Chk2 (Phospho-Thr383) Antibody.The lane on the right is treated with the antigen-specific peptide.)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
Pricing
IHC (Immunohiostchemistry) (Immunohistochemical analysis of paraffin-embedded human breast carcinoma tissue, using ITGB4 (Phospho-Tyr1510) antibody (left)or the same antibody preincubated with blocking peptide (right).)
Antibodies were produced by immunizing rabbits with synthetic phosphopeptide and KLH conjugates. Antibodies were purified by affinity-chromatography using epitope-specific phosphopeptide. Non-phospho specific antibodies were removed by chromatography usin
IHC (Immunohiostchemistry) (Immunohistochemistry analysis of paraffin-embedded human brain tissue using Caspase 1 (Phospho-Ser376) antibody. Western blot analysis of extracts from 293 cells, using Caspase 1 (Phospho-Ser376) antibody.)
Affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific phosphopeptide. The antibody against non-phosphopeptide was removed by chromatography using non-phosphopeptide corresponding to the phosphorylation site.
IF (Immunofluorescence) (Immunofluorescence analysis of transfected HeLa cells stained with the antiphospho- Tau (Tyr 18) antibody, dilution 1:200: A: Tau; B: Tau + Fyn)
WB (Western Blot) (Western blot analysis of transfeeted HeLa cell slysates: 1: Tau 2: Tau.+ Fyn 3: Tau + Src 4: non-transfeeted 5: TauY18F 6: TauY18F + Fyn 7: TauY18F + Src)
Protein phosphorylation is a process where a phosphate group is added to certain amino acid residues of a protein – usually serine (S), threonine (T), or tyrosine (Y) - by enzymes called kinases. This process is integral in controlling cellular signaling, cellular growth, and other biological functions.
Our catalog includes a wide range of phospho-specific antibodies that can accurately detect this important marker. They perform strongly in widely-used laboratory applications such as Western blot, flow cytometry, immunohistochemistry, and immunofluorescence microscopy. We value your trust in us and are committed to providing top-quality products and services. All of our antibodies are guaranteed to work for the applications and species indicated on our website & associated product pages.
What Are The Key Applications of Phospho Antibodies?
1. Western Blotting
One of the first steps a researcher can take in utilizing these phospho-specific antibodies, is to check if the antibody works using a technique referred to as “Western blot”. For those unfamiliar, Western Blot aids in showing whether the protein that the antibody recognizes is appearing at the correct/expected size. These phospho-specific antibodies should also be able to detect changes in the target protein’s phosphorylation (on/off state) when cells are stimulated in certain ways.
2. Staining of Fixed Cells (Immunocytochemistry)
Another routine use of these phospho-specific antibodies, is to test if the antibody is able to demonstrate similar performance when used on fixed cells (intact cells that have been preserved) as it did in the Western blot tests. It is an important aspect in many cases to confirm that the antibody works in actual intact cell samples. Ideally, the method used for cellular fixation should be the same as what is used in pathology labs (like using 10% formalin). To check if the antibody works well in tissue sections (FFPE), researchers will often test it on fixed cells that are processed similar to tissue samples.
3. Specificity Tests Using Peptides
In order to make sure that the antibody is only binding to the right target:
Laboratory technicians will mix the antibody with phospho-peptides (short segments of the protein containing the phosphate group modification).
If the antibody signal disappears, it is confirmation that it is binding to the correct phosphorylated location.
A more robust test is to use both the phosphorylated and non-phosphorylated (dephosphorylated) versions of the protein. The antibody should react only with the phosphorylated one.
Another method sometimes utilized is to treat the sample with an enzyme, such as alkaline phosphatase, that specifically removes phosphate groups. If the antibody signal disappears after this, it also confirms specificity.
4. Genetic Confirmation
As a final step, scientists can genetically manipulate the nucleotide sequence and alter the target protein by removing the exact site where phosphorylation happens. If the antibody no longer appears to detect the modified protein, it is strong evidence supporting the antibody being specific for that phosphorylated site.
Why Buy Phospho Antibodies Through Us?
The production laboratory adheres to strict and consistent protocols prior to releasing any of these phospho-specific antibodies:
Standard methods and proper controls in all tests to ensure high quality.
These antibodies are tested and validated in different cell types and species.
High quality control criterion to ensure each batch is consistent, so you will obtain reliable results every time.
FAQ
1. What Are Phospho-Specific Antibodies?
Phospho-specific antibodies are made to detect proteins only when they have a phosphate group linked to a specific amino acid residue. This empowers scientists understand if a protein is "turned on" or active, based on its phosphorylation state.
2. How to Detect Phosphorylated Proteins in a Western Blot?
To find out if a protein is phosphorylated using Western blot:
Use a phospho-specific antibody that binds only to the phosphorylated form of the protein.
You can also use a “regular” antibody for the same amino acid sequence of the protein that the phospho-specific antibody is binding to (but in this case, this antibody will not bind if there is a phosphate group present) in order to compare how much of it is phosphorylated versus how much is non-phosphorylated (or “total” protein, if the “normal” antibody’s epitopes are non-phospho-site-specific).
3. How to Choose the Best Antibody?
Here are some simple tips to help you pick the right antibody:
Know your target
Match your sample characteristics
Confirm the intended use is appropriate
Check “host” and “type”
Check the “quality” of the presented data/images
Appraise whether the available validation meets your needs
Submit a Question
Please complete the form below and a representative will contact you as soon as possible.
Request more Information
Please complete the form below and a representative will contact you as soon as possible.
Request a Manual
Please complete the form below and a representative will contact you as soon as possible.
Request a Quote
Please complete the form below and a representative will contact you as soon as possible.